IP Library Granted Patent US 8,071,543
Granted Patent B2
US 8,071,543 · App. 11/931,295 · Granted Dec 6, 2011

Methods of treating neurological conditions with hematopoeitic growth factors

Assignee: Sygnis Bioscience GmbH & Co. KG
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,071,543
App. No.
11/931,295
Granted
Dec 6, 2011
Kind
B2
Abstract

The present invention relates to a method of treating a neurological condition in a mammal by administering at least one hematopoietic growth factor.

Claims (8)

1. A method of reducing infarct size caused by cerebral ischemia during an operative procedure in a mammal, comprising administering to the mammal in need thereof before the operative procedure, a hematopoietic factor selected from the group consisting of mammalian granulocyte-colony stimulating factor (G-CSF), human G-CSF, a protein having at least 90% homology to SEQ ID NO: 37, a protein having at least 90% homology to SEQ ID NO: 38, a protein having at least 90% homology to SEQ ID NO: 39 to a second PEG-modified G-CSF or a combination thereof in an amount sufficient to reduce infarct size caused by cerebral ischemia during an operative procedure.

2. The method of claim 1 , wherein the operative procedure is carotid surgery.

3. The method of claim 1 , comprising administering mammalian G-CSF.

4. The method of claim 1 , comprising administering human G-CSF.

5. The method of claim 1 , comprising administering a protein having at least 90% homology to SEQ ID NO:37.

6. The method of claim 1 , comprising administering a protein having at least 90% homology to SEQ ID NO:38.

7. The method of claim 1 , comprising administering a protein having at least 90% homology to SEQ ID NO:39.

8. The method of claim 1 , comprising administering PEG-modified G-CSF.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2015
From: SYGNIS BIOSCIENCE GMBH & CO. KG.
To: REGENION REGENSBURG - BOGDAHN AIGNER GBR
Reel/Frame 034883/0377 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2015
From: REGENION REGENSBURG - BOGDAHN AIGNER GBR
To: NEUROVISION-PHARMA GMBH
Reel/Frame 034883/0387 →
Continuity (5)
Continuation 10880101 · Jun 30, 2004
Continuation In Part PCTIB0306446 · Dec 31, 2003
Continuation In Part 10659295 · Sep 11, 2003
Continuation 10331755 · Dec 31, 2002
Related Publication 20090087481A1 · Apr 2, 2009